Physician profile
James C Rice
NPI 1689733172
$1,085.32
in general payments reported to CMS, 2019-2025
13 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $125 · 2022: $14.25 · 2023: $28.23 · 2024: $134 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $395.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $178.18 | 2024-2025 | Prevymis, Zerbaxa, Dificid |
| Vifor Pharma, INC. | $144.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.57 | 2023-2025 | Livtencity |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| One Lambda, INC. | $45.43 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.70 | 2024-2025 | Xifaxan |
| Calliditas Therapeutics US INC. | $28.47 | 2024 | |
| Novo Nordisk INC | $25.26 | 2025 | Wegovy |
| Veloxis Pharmaceuticals, INC. | $23.74 | 2024 | Envarsus |
| Orphalan INC | $16.58 | 2025 | Cuvrior |
| Intercept Pharmaceuticals, INC. | $14.25 | 2022 | |
| Eurofins Viracor, LLC | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.